Previous 10 | Next 10 |
-- Proposal of one-tier board structure & appointment of three new directors -- Mechelen, Belgium; 24 March 2022, 2 1 .01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) published its annual report for th...
-- Proposal of one-tier board structure & appointment of three new directors -- Mechelen, Belgium; 24 March 2022, 2 1 .01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) published its annual report for th...
David Einhorn's 13F stock portfolio value increased from $1.49B to $1.75B this quarter. Greenlight increased Capri Holdings, ODP Group, Livanova, & Victoria’s Secret while reducing Twitter, Concentrix, & EchoStar. They also added Global Payments while dropping AerCap an...
Galapagos NV (GLPG) Q4 2021 Earnings Conference Call February 25, 2022 8:00 AM ET Company Participants Sofie Van Gijsel - Senior Director, Investor Relations Onno van de Stolpe - Chief Executive Officer Bart Filius - Chief Operating Officer Walid Abi-Saab - Chief Medical Officer Michele Manto...
Galapagos press release (NASDAQ:GLPG): FY GAAP EPS of -€1.58. Revenue of €484.85M (+1.4% Y/Y). Cash and current financial investments of €4.7 billion on 31 December 2021 Operational cash burn of €564.8 million, within the guided range. "For 2022 we anticipate a fur...
Key 2021 and post period events: Appointment of Dr. Paul Stoffels 1 as new CEO, effective 1 April 2022, following planned retirement of CEO and co-founder Onno van de Stolpe Jyseleca sales booked by Galapagos in Europe were €14.8 million out of a total in-...
Galapagos has failed to prove the mettle of its R&D pipeline in most of the programs it ran. Filgotinib's failure was a major disruption. They do have enough cash and a new CEO, so a turnaround may still happen. For further details see: Galapagos: A History Of Disrup...
Mechelen, Belgium; 03 February 2022, 22 . 01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) received a new transparency notification from EcoR1 Capital , LLC . Pursuant to Belgian transparency legislation ...
Nine presentations demonstrate Galapagos’ commitment to inflammation and the ulcerative colitis (UC) community Four new analyses from Phase 3 SELECTION and SELECTION long term extension studies of Jyseleca ® (filgotinib) provide additional insights ...
A changing of the guard is coming at biotech Galapagos (NASDAQ: GLPG) , with the announcement of a new CEO. Investors were quite happy to hear this, and consequently the stock ended the day more than 22% higher. Belgium-based Galapagos announced Wednesday afternoon that it has t...
News, Short Squeeze, Breakout and More Instantly...
2024-07-11 21:42:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Adaptimmune and Galapagos to conduct clinical proof-of-concept trial to evaluate the safety and efficacy of uza-cel (next-generation MAGE-A4 TCR T-cell therapy) produced on Galapagos' decentralized manufacturing platform in patients with head & neck cancer Uza-cel has shown encouraging resul...